Profusa Shareholders Approve PanOmics Acquisition, Debt Conversion, and Reverse Split Authorization for Nasdaq Compliance
PFSA is trading near its 52-week low of $0.129 (12% below the low).
Summary
Profusa shareholders have approved all strategic proposals at the company's 2026 Annual Meeting, including the acquisition of PanOmics, debt conversion measures to strengthen the balance sheet, and authorization for a reverse stock split. This follows previous SEC filings detailing the PanOmics acquisition, significant dilutive debt, and a Nasdaq delisting notice. The approvals are critical for Profusa to address its precarious financial position, which includes a going concern warning, and to maintain its Nasdaq listing. The company will now focus on completing the PanOmics transaction and implementing the reverse split if required.
At the time of this announcement, PFSA was trading at $0.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $671.1K. The 52-week trading range was $0.13 to $957.00. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.